| Identification | Back Directory | [Name]
CNX-419 hydrobroMide | [CAS]
1446700-26-0 | [Synonyms]
CNX-419 HBr
CO-1686 HBr
AVL-301 hydrobroMide
CNX-419 hydrobroMide
CO-1686 (hydrobroMide)
Rociletinib hydrobromide
Rociletinib hydrobromide (CO1686
Rociletinib (CO-1686,AVL-301) HBr
AVL-301 HBr salt, CNX-419 HBr salt
CO-1686 HBr salt,Rociletinib HBr salt
ROCILETINIB HYDROBROMIDE; AVL-301 HYDROBROMIDE; CNX-419 HYDROBROMIDE | [Molecular Formula]
C27H29BrF3N7O3 | [MOL File]
1446700-26-0.mol | [Molecular Weight]
636.463 |
| Hazard Information | Back Directory | [Uses]
Rociletinib hydrobromide (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively. | [in vivo]
Rociletinib (100 mg/kg/day, p.o.) demonstrates anti-tumor activity in NSCLC EGFR mutant xenograft models. Rociletinib (50 mg/kg bid, p.o.) demonstrates anti-tumor activity in human EGFR-L858R and EGFR-L858R-T790M expressing transgenic mice[1]. | [IC 50]
EGFRL858R/T790M: 21.5 nM (Ki); EGFRT790M: 303.3 nM (Ki) | [storage]
Store at -20°C | [References]
[1] Walter AO, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Sep 25. DOI:10.1158/2159-8290.CD-13-0314 |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
Musechem
|
| Tel: |
+1-800-259-7612 |
| Website: |
www.musechem.com |
|